ClinicalTrials.gg
RecruitingNCT04474301Updated Oct 7, 2026

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

An observational study in COVID-19 Infection and Melanoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,152
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in COVID-19 by M.D. Anderson Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. COVID-19 · M.D. Anderson Cancer Center.

Planned enrollment
4th of 10
1,152 · median 600
Started
2020
with 10 others
Observational
10 of 14
5 open now
Registered
4th of 14
by date

Among the 14 studies in COVID-19 by M.D. Anderson Cancer Center, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2020, is one of 10 observational ones, and was the 4th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

5 of the 14 studies in COVID-19 by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in COVID-19 by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing, isolation, seropositivity, hospitalization, loss of family or friends); COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms); health, financial and social disruptions; perceived benefits and social support; and health-related quality of life (HRQoL) in melanoma patients who participated in protocol PA15-0336.

II. Evaluate the extent to which COVID-19 experiences are associated with COVID-19-specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and HRQoL.

III. Evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.

IV. Explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.

OUTLINE:

Patients complete a survey over 10 minutes.

03

Conditions studied

  • COVID-19 Infection
  • Melanoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have signed consent for PA15-0336.

Eligibility criteria

Inclusion Criteria:

  • Patients who have signed consent for PA15-0336
  • Has an active email address and can be contacted via MyChart
  • Documentation of being alive per the cancer registry
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,152 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational (survey administration)

    Patients complete a survey over 10 minutes.

    Other: Survey Administration

Interventions

  • OtherSurvey Administration

    Complete survey

06

What researchers measure

Primary outcomes

  1. Experiences during the COVID-19 pandemic

    Including exposure, risk factors, testing, isolation, seropositivity, hospitalization, or loss of family or friends.

    Time frame: Survey completion Up to 2 months

  2. COVID-19-specific psychological distress

    Time frame: Survey completion Up to 2 months

  3. COVID-19-specific health

    Time frame: Survey completion Up to 2 months

  4. COVID-19-specific financial and social disruptions

    Time frame: Survey completion Up to 2 months

  5. COVID-19-specific perceived benefits and social support

    Time frame: Survey completion Up to 2 months

  6. COVID-19-specific health related quality of life (HRQoL)

    Time frame: Survey completion Up to 2 months

  7. Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL

    Will evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.

    Time frame: Survey completion Up to 2 months

  8. Prior lifestyle data

    Will explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.

    Time frame: Survey completion Up to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Dec 2026, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
Jul 16, 2020
StartActual
Jun 11, 2020
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04474301
Responsible party
Sponsor
First posted
Jul 16, 2020
Start date
Jun 11, 2020
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Lorenzo Cohen
Contact
lcohen@mdanderson.org
(713) 745-4260
Lorenzo Cohen
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion